Agilent, MRM Proteomics Extend Co-marketing Agreement

Jul 24, 2014

|

NEW YORK (GenomeWeb) – Agilent Technologies today announced the extension of a co-marketing agreement with MRM Proteomics.

The extension expands a deal between the companies reached in September 2012, and will allow the partners to improve their combined proteomics solutions comprising reagents kits, hardware, and software, Agilent said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.

Featured White Papers

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Stroma Liquid Biopsy, a pan-cancer biomarker panel of dysregulation derived from blood

Lipid Removal Sample Prep for Cell Response Applications

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

17

Featured Webinar

Biomarker Strategies for Optimizing Checkpoint Immunotherapy Treatment

This webinar will provide an overview of current biomarker strategies for guiding the use of combination checkpoint immunotherapies in blood cancers.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

Menu